These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22074421)

  • 1. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
    Di Stefano A; Sozio P; Cerasa LS; Iannitelli A
    Curr Pharm Des; 2011; 17(32):3482-93. PubMed ID: 22074421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiparkinson prodrugs.
    Di Stefano A; Sozio P; Cerasa LS
    Molecules; 2008 Jan; 13(1):46-68. PubMed ID: 18259129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M; Petzer JP; Viljoen F; Petzer A
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
    Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
    Eur J Med Chem; 2010 Sep; 45(9):4035-42. PubMed ID: 20646792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.
    Giorgioni G; Claudi F; Ruggieri S; Ricciutelli M; Palmieri GF; Di Stefano A; Sozio P; Cerasa LS; Chiavaroli A; Ferrante C; Orlando G; Glennon RA
    Bioorg Med Chem; 2010 Mar; 18(5):1834-43. PubMed ID: 20153654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.
    Haddad F; Sawalha M; Khawaja Y; Najjar A; Karaman R
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295587
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation.
    Di Battista V; Hey-Hawkins E
    J Pharm Sci; 2022 May; 111(5):1262-1279. PubMed ID: 35182542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
    Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
    Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in prodrug design for Parkinson's disease.
    Cacciatore I; Ciulla M; Marinelli L; Eusepi P; Di Stefano A
    Expert Opin Drug Discov; 2018 Apr; 13(4):295-305. PubMed ID: 29361853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
    Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
    J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity.
    Bizzarri BM; Tortolini S; Rotelli L; Botta G; Saladino R
    Curr Med Chem; 2015; 22(36):4138-65. PubMed ID: 26112144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving L-dopa therapy: the development of enzyme inhibitors.
    Gershanik OS
    Mov Disord; 2015 Jan; 30(1):103-13. PubMed ID: 25335824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoramidate derivates as controlled-release prodrugs of l-Dopa.
    Olatunji FP; Kesic BN; Choy CJ; Berkman CE
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2571-2574. PubMed ID: 31400939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.